{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-25-000040","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.049107+00:00","generated_at":"2026-05-22T04:35:28.244696+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Caribou Q1 net loss $40M; cuts 32% workforce, extends cash runway into H2 2027","bullets":["Cash, equivalents & securities $212.5M as of Mar 31, 2025 (down from $249.4M at Dec 31, 2024).","Net loss $40.0M vs $41.2M YoY; R&D expenses $35.5M (up from $33.8M) and G&A $9.7M (down from $14.6M).","Discontinued CB-010 lupus trial, CB-012 AML trial, and preclinical work; workforce reduced ~32% with $2.5–3.5M cash costs.","CB-010 (2L LBCL) and CB-011 (multiple myeloma) Phase 1 data expected in H2 2025 with FDA interaction for potential pivotal trial.","Licensing revenue flat at $2.4M for the quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-25-000040","json":"https://secwatch.observer/filing/0001619856-25-000040.json","markdown":"https://secwatch.observer/filing/0001619856-25-000040.md","text":"https://secwatch.observer/filing/0001619856-25-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985625000040/0001619856-25-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985625000040/crbu-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:35:28.244696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}